JADE CURY MARTINS ASFORA LINS
Projetos de Pesquisa
Unidades Organizacionais
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
LIM/56 - Laboratório de Investigação em Dermatologia e Imunodeficiências, Hospital das Clínicas, Faculdade de Medicina
4 resultados
Resultados de Busca
Agora exibindo 1 - 4 de 4
- Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel(2020) CURY-MARTINS, Jade; ERIS, Adriana Pessoa Mendes; ABDALLA, Cristina Martinez Zugaib; SILVA, Giselle de Barros; MOURA, Veronica Paula Torel de; SANCHES, Jose AntonioWith the development of new cancer therapies, systemic toxicity profile and effects on survival achieved an important improvement. However, a constellation of toxicities has emerged, even more remarkably, cutaneous adverse events. This report, developed by a board of Brazilian experts in oncodermatology, aims to establish a guideline for the dermatological care of oncologic patients. When possible, evidence-based recommendations were made, but in many cases, when strong evidence was not available, a consensus was reached, based on some data supporting therapies combined with personal experiences. (C) 2020 Sociedade Brasileira de Dermatologia.
- Cutaneous adverse events to systemic antineoplastic therapies: a retrospective study in a public oncologic hospital(2022) CEGLIO, William Queiroz Guimaraes Wiegandt; REBEIS, Marina Mattos; SANTANA, Marcela Ferreira; MIYASHIRO, Denis; CURY-MARTINS, Jade; SANCHES, Jose AntonioBackground: Mucocutaneous adverse events are common during anticancer treatment, with variable consequences for the patient and their therapeutic regimen. Objective: To evaluate the most common adverse events, as well as the drugs associated with their appearance and the consequences for cancer treatment. Methods: A retrospective study was carried out through the analysis of patients treated at the Clinical Dermatology Unit of a public oncologic hospital. Results: A total of 138 patients with 200 adverse events were evaluated. The most commonly identified adverse events were nail and periungual changes (20%), papulopustular eruptions (13%), acneiform eruptions (12%), hand-foot syndrome (6.5%), hand-foot skin reaction (6%), and xerosis (6%). The most frequently associated antineoplastic treatment groups were classical chemotherapy (46.2%), target therapy (32.3%), and other non-antineoplastic drugs used in neoplasia protocols (16.5%). Of the total number of patients, 17.4% had their treatment suspended or changed due to a dermatological adverse event. Study limitations: Retrospective study and analysis of patients who were referred for specialized dermatological examination only, not allowing the assessment of the actual incidence of adverse events. Conclusion: A wide variety of dermatological manifestations are secondary to antineoplastic treatment with several different drugs resulting, not rarely, in the interruption or modification of therapeutic regimens. (C) 2021 Sociedade Brasileira de Dermatologia.
- Mycosis fungoides and Sezary syndrome: focus on the current treatment scenario(2021) SANCHES, Jose Antonio; CURY-MARTINS, Jade; ABREU, Rodrigo Martins; MIYASHIRO, Denis; PEREIRA, JulianaCutaneous T-cell lymphomas are a heterogeneous group of lymphoproliferative disorders, characterized by infiltration of the skin by mature malignant T cells. Mycosis fungoides is the most common form of cutaneous T-cell lymphoma, accounting for more than 60% of cases. Mycosis fungoides in the early-stage is generally an indolent disease, progressing slowly from some patches or plaques to more widespread skin involvement. However, 20% to 25% of patients progress to advanced stages, with the development of skin tumors, extracutaneous spread and poor prognosis. Treatment modalities can be divided into two groups: skin-directed therapies and systemic therapies. Therapies targeting the skin include topical agents, phototherapy and radiotherapy. Systemic therapies include biological response modifiers, immunotherapies and chemotherapeutic agents. For early-stage mycosis fungoides, skin-directed therapies are preferred, to control the disease, improve symptoms and quality of life. When refractory or in advanced-stage disease, systemic treatment is necessary. In this article, the authors present a compilation of current treatment options for mycosis fungoides and Sezary syndrome. (C) 2021 Sociedade Brasileira de Dermatologia.
- A unique case of a lymphoproliferative disorder affecting the skin and uterine cervix on a male transgender(2024) CURY-MARTINS, Jade; GIANNOTTI, Marcelo A.; MIYASHIRO, Denis; PEREIRA, Juliana; SANCHES, Jose Antonio